References
- Grady D, Rubin S M, Pettiti D B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016–37
- Bush T L, Barrett-Connor E, Cowan L D, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid-Research Clinics Program follow-up study. Circulation 1987; 75: 1102–9
- Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by the vascular endothelial cells. Nature 1988; 332: 411–15
- Wilcox J G, Hatch I E, Gentzschein E, et al. Endothelin levels decrease after oral and nonoral estrogen in postmenopausal women with increased cardiovascular risk factors. Fertil Steril 1997; 67: 273–7
- Ylikorkala O, Orpana A, Puolakka J, et al. Postmenopausal hormonal replacement decreases plasma levels of endothelin-1. J Clin Endocrinol Metab 1995; 80: 3384–7
- De Visser J, Coert A, Feenstra H, et al. Endocrinological studies with (7α,17α)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD 14). Arneimitt Forsch 1984; 34: 1010–17
- Egarter C, Huber J, Leikermoser R, et al. Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints. Maturitas 1996; 23: 55–62
- Lippuner K, Haenggi W, Birkhäuser M H, et al. Prevention of postmenopausal bone loss using tibolone or conventional oral or transdermal hormone replacement therapy with 17β-oestradiol and dydrogesterone. J Bone Miner Res 1997; 12: 806–12
- Genazzani A R, Benedek Jaszman L J, Hart D M, et al. Org OD 14 and the endometrium. Maturitas 1991; 13: 243–51
- Hänggi W, Lippuner K, Riesen W, et al. Long term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein (a): a randomised study. Br J Obstet Gynaecol 1997; 104: 708–17
- Haenggi W, Linder H R, Birkhaeuser M H, et al. Microscopic findings of the nail-fold capillaries – dependence on menopausal status and hormone replacement therapy. Maturitas 1995; 22: 37–46